leukocytes

L-Leucyl-L-Leucine methyl ester hydrochloride (Leu-Leu-ome hydrochloride) is a dipeptide condensation product of L-leucine methyl ester produced by human monocytes or polymorphonuclear leukocytes. L-Leucyl-L-Leucine methyl ester hydrochloride selectively eliminates lymphocytes with cytotoxic potential and also induces lysosomal stress.

Tulathromycin A (CP 472295) is a macrolide antibiotic.

Aminopterin (4-Aminofolic acid) is a synthetic folic acid derivative whose metabolite is a competitive inhibitor of dihydrofolate reductase

CJ-13,610 is an orally active and nonredox-type inhibitor of 5-lipoxygenase (5-LOX). CJ-13,610 inhibits the biosynthesis of leukotriene B4 and regulates the expression of IL-6 mRNA in macrophages.

MIK665 (S-64315) is a small-molecule inhibitor and a myeloid cell leukemia sequence 1 (MCL1) inhibitor (IC50 = 1.81 nM) with high selectivity and cell permeability. Used in experimental research, this compound exhibits antitumor activity in hematologic malignancies such as acute myeloid leukemia.

Traxanox is an orally available diuretic.Traxanox enhances phagocytosis of yeast granules by mouse peritoneal macrophages or rat peritoneal polymorphonuclear leukocytes in vitro.Restorative effect of Traxanox on inhibition of antibody production in BALB/c mice.

Traxanox TFA is an orally available diuretic. Traxanox TFA enhances phagocytosis of yeast granules by mouse peritoneal macrophages or rat peritoneal polymorphonuclear leukocytes in vitro. Traxanox TFA restores inhibition of antibody production in BALB/c mice. Traxanox TFA is also effective in restoring antibody production in BALB/c mice. Traxanox TFA has been shown to enhance phagocytosis in BALB/c mice.

Nothofagin has antioxidant, and antithrombotic activities, it possesses anti-inflammatory activity by inhibiting hyperpermeability, expression of CAMs, and adhesion and migration of leukocytes, thereby endorsing its usefulness as a therapy for vascular inflammatory diseases.

Methyl retinoate (Retinoic acid, methyl ester) induces aseptic inflammation at the site of administration in in vivo experiments, which causes an increase in the number of leukocytes in the blood and a decrease in the levels of red blood cells and Hb.Methyl retinoate promotes spontaneous leukemia.Methyl retinoate can be Used in the treatment of gastric hypertrophy and ulcers due to vitamin A deficiency. Translated with www.DeepL.com/Translator (free version)

(+)-Guaiacin, isolated from the bark of Machilus wangchiana Chun, demonstrates potent in vitro inhibition of β-glucuronidase release in rat polymorphonuclear leukocytes (PMNs) induced by platelet-activating factor (PAF).

Alclometasone (7a-Chloro-16a-methyl prednisolone), a glucocorticoid, inhibits leukocyte release of pro-inflammatory mediators and effectively treats corticosteroid-responsive dermatoses such as atopic dermatitis, psoriasis, allergic dermatitis, and eczema [1].

LY 178002 is an effective inhibitor of 5-lipoxygenase (5-LPO), phospholipase A2 (IC50: 0.6 μM for 5-lipoxygenase). LY 178002 also inhibits cellular production of LTB4 by human polymorphonuclear leukocytes and displays relatively weak inhibition on cycloox

1-Stearoyl-sn-glycerol 3-phosphate sodium, a biologically active phospholipid, plays a crucial role in regulating cell motility, proliferation, invasion, survival, and the production of growth factors through interactions with G protein-coupled receptors (GPCR). Synthesized during the formation of membrane phospholipids, this compound typically has a low plasma concentration (approximately 100nM) and originates from various cell types, including activated platelets, epithelial cells, leukocytes, neuronal cells, and tumor cells. Its distinctive structure features stearic acid at the sn-1 position and a hydroxyl group at the sn-2 position.

β2AR agonist 4 (compound A19) is an effective selective agonist for the β2-adrenoceptor (β2-Adrenoceptor), exhibiting an EC50 of 3.7 pM. In a rat model with COPD, β2AR agonist 4 reduces the elevation of inflammatory factors and leukocytes, thereby improving lung function.

WY-50295 is an orally active and selective 5-lipoxygenase inhibitor. In rat whole blood leukocytes, WY-50295 inhibits LTB4 formation with an IC50 of 40 μM and an oral ED50 of 18 mg/kg. WY-50295 is applicable for research into asthma and other leukotriene-dependent conditions.

HZ52 is a potent, reversible 5-lipoxygenase (5-LO) inhibitor that blocks leukotriene (LTs) synthesis with an IC50 of 0.7 μM in intact human polymorphonuclear leukocytes [1].

LY255283 is a specific antagonit of leukotriene B4 (LTB4) receptor. It inhibits the production of LTB(4) in human peripheral blood polymorphonuclear leukocytes (PMNL) and in monocytes activated by calcium ionophore A23187.

L 651142 is a weak inhibitor of the platelet-activating factor receptor. It is also binding to polymorphonuclear leukocytes.

Diacetylsplenopentin HCl is used as a synthetic immunomodulator that affects the proliferation and differentiation of bone marrow stem cells without stimulating pathological immune responses beyond the balance of the immune system. This effect is specific

A1777, a selective 5-lipoxygenase inhibitor, reduces leukocytes proliferation without affecting the eosinophils of mast cells.

Gea 3162 is a potent inhibitor of ADP-induced platelet aggregation in platelet rich plasma (PRP). GEA 3162 stimulates cGMP production in granulocytes, platelets, and polymorphonuclear leukocytes.

Traxanox sodium is an orally available diuretic. Traxanox sodium enhances phagocytosis of yeast granules by mouse peritoneal macrophages or rat peritoneal polymorphonuclear leukocytes in vitro. Traxanox sodium restores inhibition of antibody production in BALB/c mice. Traxanox sodium is also effective in restoring antibody production in BALB/c mice. Traxanox sodium has been shown to enhance phagocytosis in BALB/c mice.

(±)11(12)-EET is a fully racemic version of the R/S enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes.[1][2][3] A higher proportion of 11(R),12(S)-EET is produced by the CYP450 isoforms CYP2C23 and CYP2C24, while CYP2B2 produces a higher proportion of 11(S),12(R)-EET.[3] 11(12)-EET has been shown, along with 8(9)-EET, to play a role in the recovery of depleted calcium pools in cultured smooth muscle cells.[4] It also inhibits basolateral 18-pS potassium channels in the renal cortical collecting duct at a concentration of 100 nM.[5] 11(12)-EET (50 μg/kg per day) increases adhesion of isolated peripheral blood leukocytes in a chamber coated with P-selectin and ICAM-1 but does not affect choroidal neovascularization size following laser photocoagulation.[6] It also has anti-inflammatory, angiogenic, and cardioprotective properties.[7]

PMX-205 is a cyclic hexapeptide that acts as a potent antagonist of C5a receptor (C5aR; IC50= 31 nM).1It is orally active and blocks inflammatory signaling and symptoms in animal models of colitis and allergic asthma.2,3PMX-205 is also brain penetrant and reduces neuroinflammation and neurodegeneration in an animal model of Alzheimer's disease.4 1.March, D.R., Proctor, L.M., Stoermer, M.J., et al.Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activityMol. Pharmacol.65(4)868-879(2004) 2.Jain, U., Woodruff, T.M., and Stadnyk, A.W.The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10Br. J. Pharmacol.168(2)488-501(2013) 3.Staab, E.B., Sanderson, S.D., Wells, S.M., et al.Treatment with the C5a receptor/CD88 antagonist PMX205 reduces inflammation in a murine model of allergic asthmaInt. Immunopharmacol.21(2)293-300(2014) 4.Fonseca, M.I., Ager, R.R., Chu, S.-H., et al.Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's diseaseJ. Immunol.183(2)1375-1383(2009)